Pharmaceutical giant GSK has announced a groundbreaking $2.2 billion acquisition of Rapt Therapeutics, a company known for its innovative advancements in food allergy treatment. The acquisition highlights GSK’s focus on expanding its portfolio with clinical-stage therapies, particularly ozureprubart, an anti-immunoglobulin E monoclonal antibody drug that could revolutionize food allergy care.
The Deal Breakdown
GSK will acquire Rapt Therapeutics by paying $58 per share in cash, representing a premium over Rapt’s previous $1.6 billion market cap. The deal structure includes an upfront net payment of $1.9 billion after accounting for cash on hand. Upon completion, GSK gains global rights to ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong, where Shanghai Jeyou Pharmaceutical holds current partnerships.
The transaction will proceed in two stages: first, GSK will launch a cash tender offer to acquire all outstanding shares of Rapt Therapeutics. After that, a second-step merger will finalize the acquisition for any remaining shares. The deal is projected to close in the first quarter of 2026, following regulatory approval and standard conditions.
Why Ozureprubart Stands Out
Ozureprubart is a phase 2b clinical-stage drug designed to offer prophylactic protection against food allergens. Unlike existing treatments that demand bi-weekly injections, ozureprubart only requires a 12-week dosing schedule, making it a potentially life-changing option for patients managing food allergies.
GSK plans to initiate late-stage clinical trials covering both adults and children at risk, positioning ozureprubart as a best-in-class treatment in the food allergy space. This innovation aligns with GSK’s mission to provide effective, long-term solutions for patients with high unmet medical needs.
Market Impact
The announcement has already had a significant market impact, with RAPT stock surging 65.76% in the past week to $57.57, nearing its 52-week high. GSK’s move also reflects its intention to fill key gaps in its portfolio by entering new therapeutic areas like food allergy and urticaria, where it has not conducted prior clinical-stage trials.
Expert Commentary
“Ozureprubart is a unique opportunity for us to expand in the autoimmune sector, particularly in food allergy treatments, where patients and physicians need more effective solutions,” said Tony Wood, GSK’s Chief Scientific Officer. Analysts from Leerink Partners underscore the strategic fit, noting minimal overlap in GSK’s clinical assets, which will likely reduce regulatory hurdles.
Looking Ahead
The results from ozureprubart’s ongoing phase 2b trials are expected by 2027, and if successful, the acquisition could propel GSK into a leadership position in allergy medicine. It may also strengthen relationships with physicians and patients seeking alternative, less burdensome treatment options.
Related Product Spotlight
If you or a loved one is managing a food allergy, discover Eczema Itch Relief Cream from AllergyStore, designed to soothe sensitive skin. While awaiting advancements like ozureprubart, effective skincare products can help manage allergic reactions and offer relief. Learn more here.
